| Mrs Tracey M Blackton-kopp, RN | |
|
261 Connecticut Dr, Burlington, NJ 08016-4177 | |
| (609) 387-7322 | |
| Not Available |
| Full Name | Mrs Tracey M Blackton-kopp |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 261 Connecticut Dr, Burlington, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245353531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 26NO11913500 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Tracey M Blackton-kopp, RN 7 Castleton Ln, Moorestown, NJ 08057-3049 Ph: (856) 642-9798 | Mrs Tracey M Blackton-kopp, RN 261 Connecticut Dr, Burlington, NJ 08016-4177 Ph: (609) 387-7322 |
News Archive
BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea.
MedAptus(R), the market leader for charge capture technologies, today announced that Caritas Christi Health Care, also based in Boston, has implemented the company's Intelligent Charge Capture suite for revenue and compliance enhancement initiatives. The organization selected MedAptus' Practice Plus Edition on BlackBerry smartphone devices and web-enabled workstations for the capture of physician inpatient charges. In addition, Caritas Christi is rolling out the MedAptus Facility Edition for the capture of outpatient clinic charges, starting in the area of cardiology.
Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.
› Verified 4 days ago
Jacqueline Lee Todd, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr Ste 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Constantin Vintilescu, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Joanne Petit-homme, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Karen Coley, LPN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Leonida D. Matibag, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr Ste 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Marcia Greyson, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 328 High St, Burlington, NJ 08016 Phone: 929-557-9059 | |
Mrs. Esther A Woods-bartels, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1003 Sunset Rd, Burlington, NJ 08016 Phone: 856-520-9875 Fax: 732-510-5976 |